The University of Arizona

TCAP - Randomized Trial of Ticagrelor for Severe Community Acquired Pneumonia


To assess the efficacy and safety of 90 days of oral ticagrelor in patients hospitalized with severe community acquiresd pneumonia (CAP).  The primary objective is to reduce all-cause mortality in the ticagrelor group compared to the placebo group.

Gordon Bernard AstraZeneca